^
    No biomarker
    Merkel Cell Carcinoma
    avelumab
    Sensitive: A1 - Approval
    No biomarker
    Merkel Cell Carcinoma
    pembrolizumab
    Sensitive: A1 - Approval
    No biomarker
    Merkel Cell Carcinoma
    EP
    Sensitive: A2 - Guideline
    No biomarker
    Merkel Cell Carcinoma
    nivolumab
    Sensitive: A2 - Guideline
    No biomarker
    Merkel Cell Carcinoma
    cisplatin
    Sensitive: A2 - Guideline
    No biomarker
    Merkel Cell Carcinoma
    carboplatin
    Sensitive: A2 - Guideline
    No biomarker
    Merkel Cell Carcinoma
    carboplatin + etoposide oral
    Sensitive: A2 - Guideline
    No biomarker
    Merkel Cell Carcinoma
    topotecan
    Sensitive: A2 - Guideline
    No biomarker
    Merkel Cell Carcinoma
    CAV
    Sensitive: A2 - Guideline
    No biomarker
    Merkel Cell Carcinoma
    AST-008
    Sensitive: B - Late Trials
    ARID2 mutation
    Merkel Cell Carcinoma
    Immunotherapy
    Sensitive: C3 – Early Trials
    NTRK1 mutation
    Merkel Cell Carcinoma
    Immunotherapy
    Sensitive: C3 – Early Trials
    PD-L1 expression
    Merkel Cell Carcinoma
    avelumab
    Sensitive: C3 – Early Trials
    PD-1 expression
    Merkel Cell Carcinoma
    Immunotherapy
    Sensitive: C3 – Early Trials
    DLL3 expression
    Merkel Cell Carcinoma
    rovalpituzumab tesirine
    Sensitive: C4 – Case Studies
    PD-L1 negative
    Merkel Cell Carcinoma
    avelumab
    Sensitive: C4 – Case Studies
    NCAM1 expression
    Merkel Cell Carcinoma
    nivolumab
    Sensitive: C4 – Case Studies
    NKX2-1 expression
    Merkel Cell Carcinoma
    avelumab
    Sensitive: C4 – Case Studies